The use of recombinant ovine IL-1beta and TNF-alpha as natural adjuvants and their physiological effects in vivo.
In the present study we have investigated the use of recombinant ovine IL-1beta and TNF-alpha both alone and in combination, as natural adjuvants in vaccination trials in sheep. Initial experiments were conducted to investigate the physiological effects of the cytokines in vivo and determine what dose could be administered without adverse pyrogenic effects. Even at the maximum dose tested (100 microg) the only significant physiological effect was a transient increase in body temperature of approximately 2 degrees C in sheep injected with TNF-alpha. Administration of either cytokine had profound effects on the levels of circulating leucocytes for up to 5 days postinjection. The incorporation of either IL-1beta or TNF-alpha in aqueous or Al(OH)3 vaccine formulations enhanced antibody responses to a recombinant antigen from the cestode parasite Taenia ovis. The addition of IL-1beta to aqueous vaccine formulations increased antibody responses 15-20-fold and in Al(OH)3 formulations by three to six fold. TNF-alpha stimulated 1.5 to six-fold and 2.5 to seven-fold increases in antibody levels in aqueous and Al(OH)3-based formulations, respectively, in a dose-dependent manner. The addition of either cytokine to Quil A or IFA vaccines did not enhance the antibody levels elicited. When 10 microg of both IL-1beta and TNF-alpha were incorporated in the aqueous or Al(OH)3 vaccine formulations, increases of 21-fold and 25-fold, respectively, were observed in antibody levels. The adjuvant activity of IL-1beta and TNF-alpha in combination in the Al(OH)3-based vaccine resulted in antibody levels commensurate with those obtained using Quil A or IFA.
Rothel
J S
JS
The University of Melbourne, Molecular Parasitology Laboratory, Veterinary Clinical Centre, Werribee, Australia. jrothel@csl.com.au
Seow
H F
HF
Lightowlers
M W
MW
Parry
B W
BW
Gauci
C
C
Hurst
L
L
Mucha
M J
MJ
Corner
L A
LA
Wood
P R
PR
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000367:Age Factors; D000536:Aluminum Hydroxide / Q000276:immunology; D000818:Animals; D004797:Enzyme-Linked Immunosorbent Assay; D007375:Interleukin-1 / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D012756:Sheep; D012757:Sheep Diseases / Q000276:immunology; D013622:Taeniasis / Q000276:immunology / Q000662:veterinary; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000494:pharmacology*; D014614:Vaccines, Synthetic / Q000276:immunology
D000276:Adjuvants, Immunologic; D007375:Interleukin-1; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D014614:Vaccines, Synthetic; D000536:Aluminum Hydroxide